$1.57
+0.19 (+13.77%)
Open$1.21
Previous Close$1.38
Day High$1.62
Day Low$1.18
52W High$6.99
52W Low$0.95
Volume—
Avg Volume81.0K
Market Cap4.42M
P/E Ratio—
EPS$-5.43
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,370.1% upside
Current
$1.57
$1.57
Target
$38.78
$38.78
$26.82
$38.78 avg
$44.92
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.63M | 2.53M | 2.93M |
| Net Income | 21.2K | 20.0K | 19.6K |
| Profit Margin | 0.8% | 0.8% | 0.7% |
| EBITDA | 30.9K | 30.5K | 37.6K |
| Free Cash Flow | 17.8K | 22.0K | 24.1K |
| Rev Growth | -5.2% | +23.9% | +20.0% |
| Debt/Equity | 0.27 | 0.26 | 0.26 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |